Stay updated on Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added, and the prior funding-status notice and Revision: v3.4.1 note were removed.SummaryDifference0.5%

- Check21 days agoChange DetectedAdded a government funding/status notice regarding the NIH Clinical Center. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check28 days agoChange DetectedUI updates include adding a 'Show glossary' option, introducing a new label 'Last Update Submitted that Met QC Criteria,' updating the revision to v3.4.0, and capitalization tweaks for 'No FEAR Act Data'. These changes do not affect study content, eligibility criteria, or results.SummaryDifference0.2%

- Check35 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded a Locations section listing Florida. Updated the page revision to v3.3.3; the Florida Locations label and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%

- Check85 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in HR-Competent & Deficient Tumors Clinical Trial page.